Newsfeeds - Spark Newswire

1 minute read

SVB Leerink Maintains Market Perform on Intercept Pharmaceuticals, Raises Price Target to $18

Today, 7:55 AM

SVB Leerink analyst Thomas Smith maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Market Perform and raises the price target from $17 to $18.

ICPT

1 minute read

Needham Maintains Buy on Intercept Pharmaceuticals, Raises Price Target to $26

By Benzinga Newsdesk

Today, 7:55 AM

Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and raises the price target from $22 to $26.

ICPT

8 minute read

Earnings

Earnings Scheduled For March 2, 2023

By Benzinga Insights

Today, 7:55 AM

Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.

ABEV

1 minute read

RBC Capital Maintains Sector Perform on Intercept Pharmaceuticals, Raises Price Target to $18

By Benzinga Newsdesk

Today, 7:55 AM

RBC Capital analyst Brian Abrahams maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Sector Perform and raises the price target from $15 to $18.

ICPT

1 minute read

AT&T, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday

By Lisa Levin

Today, 7:55 AM

U.S. stocks traded lower, with the Dow Jones dropping over 300 points on Wednesday. Here are some big stocks recording gains in today’s session.

EHTH

1 minute read

Raymond James Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $26

By Benzinga Newsdesk

Today, 7:55 AM

Raymond James analyst Steven Seedhouse maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $27 to $26.

ICPT

1 minute read

On Jan 14, Intercept Pharmaceuticals And Unit Entered Into A Settlement Agreement With Optimus Pharma Pvt. And Optimus Drugs Pvt.; Granted Optimus Non-exclusive, Royalty-Free License To Commercialize Generic Version Of Ocaliva In U.S. From April 26, 20…

By Benzinga Newsdesk

Today, 7:55 AM

- Form 8 Filing

ICPT

2 minute read

Intercept Announces Efficacy And Safety Data From Phase 3 REGENERATE Study In Liver Fibrosis Fue To NASH To Be Presented At NASH-TAG Conference 2023 Jan 6-7

By Benzinga Newsdesk

Today, 7:55 AM

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023.

ICPT

5 minute read

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 7:55 AM

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

ACLX

1 minute read

STAT News Reporter Adam Feuerstein Tweets “Intercept Pharmaceuticals Down 10% Because OCA’s Future In NASH Looks Bleaker. Investors Really Want Intercept To Ditch NASH And Focus On The Approved PBC Indication”

By Benzinga Newsdesk

Today, 7:55 AM

https://twitter.com/adamfeuerstein/status/1604856612514037761